Forty Seven is a biotechnology company that discovers and develops immuno-oncology therapies for the treatment of cancer... Read more
Forty Seven is a biotechnology company that discovers and develops immuno-oncology therapies for the treatment of cancer... Read more
News
May 10, 2022
BioCentury
Forty Seven, Inc.: Pheast: Forty Seven founders reunite for precision macrophage combos
Apr 09, 2020
Pharmabiz
Forty Seven: Gilead completes acquisition of clinicalstage immunooncology company, Forty Seven for US$ 4.9 billion
Apr 07, 2020
Medical Buyer
Forty Seven: Gilead Completes Acquisition Of Forty Seven Inc
Apr 06, 2020
themarketsdaily
Forty Seven: Forty Seven Inc (NASDAQ:FTSV) Insider Sells $7,556,786.90 in Stock
Mar 30, 2020
Seeking Alpha
Forty Seven: Gilead nearing finish line on Forty Seven buy
Mar 22, 2020
Unique Finance
Forty Seven: Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
Mar 21, 2020
FinSMEs
Forty Seven: Gilead To Buy Forty Seven, for $4.9 Billion
Mar 20, 2020
Seeking Alpha
Forty Seven: Forty Seven EPS beats by $0.10
Mar 17, 2020
MarketScreener
Forty Seven: FORTY SEVEN ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of FTSV and Encourages Investors to Contact the Firm
Mar 12, 2020
Pharmaceutical Business Review
Forty Seven: Forty Seven, Rocket collaborate on new treatment for Fanconi Anemia
Forty Seven, Inc. Competitors
1
2
3
4
5
6
7
8
9
10